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Here we report the ability of the tick Ixodes scapularis, the
main vector of Lyme disease in theUnited States, to actively and
specifically affect the host proteolytic activity in the sites of
infestation through the release of a cystatin constituent of its
saliva. The cystatin presence in the saliva was verified both bio-
chemically and immunologically. We named the protein sia-
lostatin L because of its inhibitory action against cathepsin L.
We also show that the proteases it targets, although limited in
number, have a prominent role in the proteolytic cascades that
take place in the extracellular and intracellular environment. As
a result, sialostatin L displays an antiinflammatory role and
inhibits proliferation of cytotoxic T lymphocytes. Beyond
unraveling another component accounting for the properties of
tick saliva, contributing to feeding success and pathogen trans-
mission, we describe a novel tool for studying the role of papain-
like proteases in diverse biologic phenomena and a protein with
numerous potential pharmaceutical applications.
Access to a nutritious bloodmeal has been gained independ-
ently numerous times and in various families and orders during
invertebrate evolution (1). In contrast to other successful
arthropod bloodsuckers, which feed rapidly, hard ticks feed on
their hosts for several days (2). As a consequence, they have
evolved a series of strategies to circumvent host defenses during
their prolonged meal. Among them, the shedding of saliva in
the sites of bite(s) possesses a critical role (3). Tick saliva con-
tains a broad repertoire of potent pharmacologic molecules
with vasoactive, antihemostatic, antiinflammatory, and immu-
nomodulatory action (4). A serious side effect of this saliva
action in sites of infestation is facilitation of the transmission of
tick-borne pathogens (5).
Previous sialotranscriptome work shed light on the salivary
complexity of the hard tick Ixodes scapularis (6). Large num-
bers of protease inhibitors were found to be expressed in the
tick salivary glands, including a potentially secreted peptide
with mature molecular mass of 12.5 kDa containing the con-
served cystatin domain. Cystatins are natural tight binding
reversible inhibitors of papain-like cysteine proteases that, in
turn, have traditionally been considered as mediators of the
terminal bulk proteolysis inside the lysosome. As a result, the
vertebrate cystatins have been the focus of extensive research as
the guardians or regulators that ensure protection of cells and
tissues against the undesirable scission of peptide bonds and
damage that could be caused when cysteine proteases are
released outside their normal compartment.
Within the last decade, a series of elegant studies changed the
limited housekeeping view about cysteine proteases and
showed their much more expanded and specific role in certain
aspects of vertebrate biology (7). Besides their implication in
antigen presentation (8) and immune system development (9),
they are also involved in epidermal homeostasis (10), neovas-
cularization (11), extracellular matrix degradation and neutro-
phil chemotaxis during inflammation (12, 13), apoptosis (14),
and (last but not least) proliferation of malignant cells and
their subsequent invasion into healthy tissues during metas-
tasis (15, 16).
Since the first description of chicken eggwhite cystatin in the
late 1960s (17), a body of information has been accumulated for
this superfamily of proteins present in vertebrates, inverte-
brates, plants, and protozoa. Cystatins are further subdivided
into three individual families, namely 1, 2, and 3. Family 1mem-
bers (also known as stefins) are cytosolicmoleculeswith neither
disulfide bonds nor carbohydrates. Family 2 contains all of the
secreted cystatins that are mainly found in biologic fluids; they
form two disulfide bridges, and they do not bear sugars. In con-
trast to the members of the previous two families, which pos-
sess a single cystatin-like domain and display low molecular
mass (11–14 kDa), each family 3 cystatin (also known as kini-
nogens) is made of several cystatin modules, thus being rela-
tively larger molecules (60–120 kDa) (18).
Secreted cystatins have been found in various nonvertebrate
organisms, with those expressed by nematode parasites already
shown to play a role of cardinal importance in evasion of the
host defense system and inmodulation of the immune response
(19). Although members of the cystatin family are present in
ectoparasites, too, including ticks, little is known of their spec-
ificity or function. A recent study showed that a cystatin is
important for the feeding success of the tick Amblyomma
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americanum, but the target enzymes and the mechanism of
action remain still unknown (20).
Here we describe for the first time expression of an active
family 2 cystatin found in the saliva of I. scapularis. The
sequence divergence of the protein, compared with that of
other members of the same family, results in unique and novel
target specificity directed among the others against cathepsin L,
so that we named the protein sialostatin L. We further show
that tick saliva displays an anti-cathepsin L activity that can be
attributed to its cystatin component. Finally, we demonstrate
that sialostatin L has an antiinflammatory action and reduces
the proliferation of CTL. Because this novel inhibitor can be
expressed in relatively high amounts in bacteria, many applica-
tions of medical importance based on its relatively stringent
specificity can be tested in the future.
EXPERIMENTAL PROCEDURES
Unless otherwise indicated, the protocols followed standard
procedures (21), and all of the experiments were performed
at room temperature (25  1 °C). All water used was of
18-megaohm quality, produced by a MilliQ apparatus (Milli-
pore Corp., Bedford, MA).
Bioinformatic Tools—BLAST searches (22) were used to
identify family 2 cystatin genes in different organisms based on
their sequence similarity with previously characterized family
members. Multiple sequence alignments were done using the
ClustalW (23) of the ClustalW Service at the European Bioin-
formatics Institute (available on the World Wide Web at
www2.ebi.ac.uk/clustalw), and the phylogenetic dendrograms
were visualized with the TreeView software (24). To obtain a
list of cystatin sequences, we used three iterations of PSIBLAST
with an E value cut-off of 0.01, retrieved all matches from the
nonredundant protein data base, and selected only those
sequences that started with a Met and had fewer than 220
amino acids (aa)2 and more than 2 cysteines. Next, this subset
was submitted to the SignalP server (25), and, when existent,
the signal peptide was removed. This final set was used as input
to the ClustalX analysis.
Expression, Purification, and Sequence Verification of Sia-
lostatin L—PCR was performed on the sialostatin L cDNA
(NCBI accession number gi22164282) originating from a
TriplEx2 cDNA clone, described in our previous work (6).
Primers (forward, 5-GCCCATATGACTGGTGTTTTCGGT-
GGCTACAGCGAGAGG-3; reverse, 5-GCCCTCGAGCTAT-
GCGGCTTCACACTCGAAGGGGCTGAC-3) were designed
to remove the signal sequence (see above), insert an ATG codon
directly upstream of the first codon of the mature peptide
sequence, and insert NdeI and XhoI restriction sites that
allowed cloning into the pET17b bacterial expression vector.
The expression vector was moved into Escherichia coli strain
BL21(DE3)pLysS for expression. Cultures (1 liter) were inocu-
lated and grown to an OD of 0.6–1.0 and induced by adding
isopropyl 1-thio--D-galactopyranoside to a concentration of 1
mM.After 3 h, the cultureswere harvested, and inclusion bodies
were prepared using previously described methods (26). The
inclusion bodieswere dissolved in 6Mguanidine hydrochloride,
20 mM Tris-HCl, pH 8.0, and reduced with 10 mM dithiothrei-
tol. Sialostatin L was refolded in a large volume of 20 mM Tris
HCl, pH 8.0, 300 mM NaCl, and stirred overnight at 4 °C. The
refolded protein was concentrated with a tangential flow filtra-
tion device and purified by gel filtration chromatography on
Sephacryl S-100 followed by anion exchange chromatography
onQ-Sepharose. Dialysis followed against 20mMTris-HCl, pH
7.4, 150 mM NaCl. Potential lipopolysaccharide contamination
was removed using the END-XB15 endotoxin affinity resin
(Associates of Cape Cod Inc., East Falmouth, MA). Final pro-
tein concentration was determined by measuring protein
absorbance at 280 nm. Before use, protein integrity was verified
by mass spectrometry.
Enzymatic Assays—Apparent inhibition constants of sia-
lostatin L for various proteases were obtained as described ear-
lier (27, 28) by measuring the loss of enzymatic activity at
increasing concentrations of inhibitor in the presence of a flu-
orogenic or chromogenic enzyme substrate in large excess.
The purified enzymes tested against sialostatin L were as
follows: human cathepsin H, S, and L; calpain; recombinant
human cathepsin V, X/Z/P, and E; legumain; recombinant
mouse cathepsin C (all purchased from Calbiochem); papain;
human cathepsin D; G, elastase; bovine cathepsin B; recombi-
nant human caspase 3 (all purchased from Sigma); and bovine
trypsin (Roche Applied Science). Calculation of the final molar
concentration of the enzymes used during the assays was done
as described previously (29).
Assay buffers used were as follows: 100 M NaAc, pH 5.5, 100
mM NaCl, 1 mM EDTA, 1 mg/ml cysteine, and 0.005% Triton
X-100 for cathepsin B, C, H, L, and S and papain; 25 mMNaAc,
pH 5.5, 100 mM NaCl, and 5 mM dithiothreitol for cathepsin V;
25mMNaAc, pH4.0, 1mg/ml cysteine, and 0.01%TritonX-100
for cathepsin X/Z/P; 50 mM NaAc, pH 4.0, 100 mM NaCl, and
0.01% Triton X-100 for cathepsin D and E; 20 mM Tris, pH 7.5,
100 mM NaCl, 0.4 mM CaCl2, 1 mg/ml cysteine, and 0.01% Tri-
ton X-100 for calpain; 100 mM Hepes, pH 7.5, for cathepsin G;
50mMNaAc, pH5.0, and 100mMNaCl for human legumain; 50
mM Hepes, pH 7.4, 100 mM NaCl, 10 mM dithiothreitol, 1 mM
EDTA, and 0.1%CHAPS for caspase 3; and 100mMTris, pH8.0,
and 0.01% Triton X-100 for elastase and trypsin.
Substrates, used in a 0.25 mM final concentration, were pur-
chased from Calbiochem: N-carbobenzyloxy-Arg-Arg-7- amino-
4-methylcoumarin for cathepsin B, L, and papain; H-Arg-7-ami-
no-4-methylcoumarin for cathepsin H; and N-succinyl-Leu-Tyr-
7-amino-4-methylcoumarin for calpain. The following were from
R&D Systems (Minneapolis, MN): (7-methoxy- coumarinyl)-
acetyl-Arg-Pro-Lys-Pro-Val-Glu-norvaline-Trp-Arg-Lys(2,4-
dinitro-phenyl)-NH2 for cathepsin S; N-carbobenzyloxy-Leu-
Arg-7-amino-4-methylcoumarin for cathepsin V, L, and C; (7-
methoxycoumarinyl)acetyl-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-
Lys(2,4-dinitrophenyl)-OH for cathepsinX/Z/P; and (7-methoxy-
coumarinyl)acetyl-Pro-Leu-Gly-Leu-N-3-(2,4-dinitrophenyl)-L-
2,3-diaminopropionyl-Ala-Arg-NH2 for cathepsin D and E. The
following were from Bachem Bioscience (King of Prussia, PA):
N-carbobenzyloxy-Val-Val-Arg-7-amino-4-methylcoumarin for
cathepsin S; N-acetyl-Ile-Glu-Thr-Asp-7-amino-4-methylcou-
2 The abbreviations used are: aa, amino acid(s); CTL, cytotoxic T lymphocytes;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol.
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marin for caspase 3, and N-carbobenzyloxy-Ala-Ala-Asn-7-
amino-4-methylcoumarin for human legumain. The following
were from Sigma: N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide for
cathepsin G; N- succinyl-Ala-Pro-Ala-7-amino-4-methylcouma-
rin for elastase; and Na-benzoyl-DL-arginine-4-nitroanilide for
trypsin.
Production of Polyclonal Sera—DNA vaccination technology
was employed for the sialostatin L immunization of SwissWeb-
ster mice as described by Oliveira et al. (30).
Tick Saliva Fractionation—Tick saliva was obtained by
inducing partially engorged adult female I. scapularis to salivate
into capillary tubes using the modified pilocarpine induction
method (31). Microfractionation of tick saliva by reverse-phase
high pressure chromatography was achieved with a 0.3 
150-mm C8 Magic column (Michrom Bioresources, Inc.,
Auburn, CA) perfused at 2 or 5 l/min using an ABI 140D
pump and 785A UV detector from Applied Biosystems (Foster
City, CA). Solution A contained water and 0.1% formic acid,
and solutionB contained 25% acetonitrile inmethanol and 0.1%
formic acid. After injecting the sample (previously equilibrated
with 10% methanol and containing 0.2% formic acid) into the
column, a gradient from 10 to 95% Bwas imposed for 20min at
a flow rate of 5 l/min. After this time, the flow rate was
decreased to 2 l/min. Fractions were collected using the Pro-
bot machine from Dionex (Sunnyvale, CA) at 1-min intervals
on 96-microwell plates containing various solutions as
described under “Results.”
Cell Cultures—Mouse cell line CTLL-2 (CTL) was obtained
from the American Type Culture Collection (Manassas, VA).
Cells were cultured at 37 °C in 5% CO2 in a humidified incuba-
tor. The culture medium was RPMI 1640 with Glutamax I and
25 mM Hepes buffer (Invitrogen) supplemented with 10% fetal
bovine serum (Cambrex BioScience Walkersville, Inc., Walk-
ersville, MD), 4.5 g/liter filter-sterile glucose (Mallinckrodt
Chemical, Paris, KY), and 10% rat T-STIMTM with concanava-
lin A (rat IL-2 culture supplement; BD Biosciences). Initial
inoculation densities were 1–2  104 viable cells/ml, and cells
were subcultured before reaching 2 105 cells/ml.
Cell Proliferation Assays—The whole procedure was per-
formed at 37 °C. CTLL-2 cells (2.5  103/well) were seeded in
96-well polystyrene tissue culture-treated plates (Corning
Glass). Sialostatin L was added to the cultures in various final
molar concentrations ranging from 1 to 10 M. As a negative
control, cells were cultured in parallel in the presence of 10 M
Anopheles gambiae annexin B9, also overexpressed in bacteria
(32, 33). Prior to their addition to cell cultures, the proteins
were preincubated for 3 h with 100g/ml polymyxin B (Sigma)
to eliminate the possibility that lipopolysaccharide, potentially
present in the recombinant protein preparations, could inter-
fere with the final results of the assay, and polymyxin B was
added (in the above mentioned concentration) in the cell cul-
turemedium too. Cell proliferation assays were performed 3–4
days post-culture inoculation using the CellTiter 96 aqueous
nonradioactive cell proliferation assay kit (Promega, Madison,
WI). Briefly, 40 l of MTS solution was added to each well. MTS
solution contains 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and phena-
zine methosulfate. It is bioreduced by the cells into a formazan
product soluble in tissue culture medium that absorbs at 490 nm.
After a 4-h incubation of the cells withMTS, the 490-nm absorb-
ance of the plate was determined using a Versamax microplate
reader linked to SOFTmax Pro 3.0 software (Molecular
Devices, Sunnyvale, CA). The absorbance displayed by the cells
at the time of seeding in the plate (culture inoculation) was
considered as zero absorbance. The difference in cell prolifera-
tion was additionally monitored by counting their population
under the microscope using a Neubauer hemocytometer.
Paw Edema Assay—Female C57BL/6 mice, 6–8 weeks old,
were purchased from the Jackson Laboratory (Bar Harbor,ME)
andmaintained in theNIAIDAnimal Care Facility (Twinbrook
3 Building) under pathogen-free conditions in temperature-
controlled rooms and receiving water and food ad libitum. All
treatments were performed in accordance with Ref. 64. The
carrageenan-induced hind paw inflammation model was used
to investigate the potential antiinflammatory role of sialosta-
tin L. Prior to each injection, the basal footpad thickness of
each mouse was recorded using a caliper (Mitutoyo America
Corp., Aurora, IL). Subsequently, 50l of carrageenan (2% in
saline) was administered by intraplantar injection in each
footpad in the absence or presence of different concentra-
tions of polymyxin B-treated sialostatin L (see above). Con-
trol groups of mice received the same volume of saline (vehi-
cle) in the presence or absence of sialostatin L. As an index of
edema formation, paw thickness was then measured at 1, 4,
and 24 h postinjection.
Myeloperoxidase Activity Assay—Tissue myeloperoxidase
activity assay was performed as an index of granulocyte recruit-
ment, as previously described (34). Briefly, the injected paws
were cut at 4 h post injection (the time point at which edema
peaks) and weighed prior to their homogenization in 2 ml
of 0.5% hexadecyl-trimethylammonium bromide phosphate-
buffered solution (pH 6.0). The homogenates were then centri-
fuged at 13,000 g for 3 min. Three aliquots of each superna-
tant were then transferred into 96-well plates before the
addition of a solution containing 3,3-dimethoxybenzidine and
1% hydrogen peroxide. In parallel, dilutions of pure myeloper-
oxidase (Sigma) were used for the construction of a standard
curve (OD as a function of units of enzyme activity). OD read-
FIGURE 1. Comparison of sialostatin L sequencewith those of other known family 2 cystatins. A, phylogenetic dendrogram of the family 2 cystatins from
vertebrates, invertebrates, and plants. Blue, members described to date from ticks; red, all members described in nematodes. The names of the sequences are
composedof five letters (obtained from the first three letters of thegenusnameand the first two letters of the species) followedby theNCBI accessionnumber.
B, multiple-sequence alignment of the two putative secreted cystatins expressed in the salivary glands of I. scapularis (sialostatin L and I_scapularis_cyst_2,
NCBI accession numbers 22164282 and 67083499, respectively) with secreted cystatins of vertebrate origin (cyst_SA, cyst_S, cyst_SN, cyst_D, cyst_C, chick_cyst,
rat_salivary_cyst_S, cyst_E/M, cyst_F, NCBI accession numbers NP_001313, NP_001890, NP_001889, NP_001891, NP_000090, P01038, P19313, NP_001314,
andNP_003641, respectively). Amino acids denotedwith ablue color are conserved in 100%of theproteins presented in the alignment, those shownwith a red
color are conserved in 80%of them, and thosewith a yellow color are conserved in 60%of them. T, aa substitutions revealed specifically in tick cystatins; dashes,
thePWdipeptide found inmost cystatins studied todate (positions114–115);dots, a tripeptidewith the sequenceSND (or substitutionswith chemically similar
aa) (positions 41–44) that is conserved in all cystatins that inhibit legumain (cystatins C, E/M, and F).
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ings at 450nmwere taken at 1min (timepoint corresponding to
the linear portion of the enzymatic reaction) using a spec-
trofluorimeter linked to the SOFTmaxPro 3.0 software (Molec-
ular Devices, Sunnyvale, CA). The myeloperoxidase activity
detected in the paws was expressed as units of enzyme/g of
tissue. A unit of myeloperoxidase activity was defined as that
converting 1 M of hydrogen peroxide to water in 1 min at
22 °C.
Statistical Analysis—The statistical differences among the
experimental groups in the quantitative experiments were
determined by analysis of variance using the Tukey test for
multiple comparisons. A p value of 0.05 or less was considered
to be statistically significant.
RESULTS
The aa sequence of the cystatin (NCBI accession number
22164282) found to be expressed in the salivary glands of I.
scapularis (6) displays all of the characteristics of the family 2
cystatins. In addition to the secretion signal and the conserved
QXVXG module, two disulfide bonds are formed in proximity
to the carboxyl terminus, typical for all secreted cystatins (18).
On the other hand, multiple-protein sequence alignment with
vertebrate and invertebrate family 2 and plant members shows
that all cystatins of tick origin cocluster and are divergent from
the already known and extensively studied vertebrate, nema-
tode, and plant homoorthologs (Fig. 1A). An aa sequence com-
parison of the tick cystatin with vertebrate-secreted cystatins
(most of them found in saliva also) and an additional potentially
secreted cystatin from the salivary glands of I. scapularis (NCBI
accession number 67083499) is shown in Fig. 1B. It uncovers a
series of tick-specific aa substitutions (shownwith aTabove the
alignment) and a relative short sialostatin L N terminus. Fur-
ther, substitution of the PW dipeptide (positions 114–115;
shown with dashes above of the alignment) is impressive,
because it is present in most of the known (to date) cystatins.
Previous work of Alvarez-Fernandez et al. (35) showed that a
tripeptide with the sequence SND (or substitutions with chem-
ically similar aa) is conserved in all cystatins that inhibit legu-
main (cystatins C, E/M, and F). This tripeptide is also absent
from sialostatin L (positions 41–44; shown with dots above the
alignment). In conclusion, certain aa substitutions revealed in
the sialostatin L sequence could potentially account for a novel
target repertoire.
Since it is known that family 2 cystatins are not subjected to
any kind of post-translational modifications, we decided to
overexpress sialostatin L in bacteria. Indeed, the recombinant
cystatin was active, inhibiting papain, the “archetype” of family
C1 of the clanCAcysteine proteases (29).Within the vertebrate
members of the family, cathepsins L, V,C, andXwere inhibited,
whereas only a slight inhibition (30%) of human cathepsin B
was achieved at 10 M final concentration. The effect of sia-
lostatin L presence in the proteolytic activity of the abovemen-
tioned enzymes is presented in Fig. 2A. No inhibition could be
detected for other members of the papain-like superfamily
(cathepsins H and S; see “Note Added in Proof”), although they
show high sequence similarity to cathepsin L. The same holds
true for cysteine proteases outside the C1 family (human cal-
pain family C2, human legumain family C13, human caspase 3
FIGURE2.Proteolytic enzymestargetedbysialostatinL.A, papain, cathepsin
L, cathepsin V, cathepsin C, and cathepsin X are targeted by the inhibitor. In the
case of cathepsin B, only 30% inhibition was detected in the presence of 10 M
sialostatinL. Theabscissa represents sialostatinL concentration (M) in log10 scale,
and the ordinate shows the percentage of remaining enzymatic activity in the
presence of sialostatin L. B, lower inhibitor concentration is necessary for the
same percentage of cathepsin L inhibition to be achieved, since the concentra-
tion of the enzyme used in the assays decreases by 2-fold (from 40 pM to 20 and
10 pM, respectively). Each experiment was performed in triplicate. The abscissa
represents sialostatin L concentration (M) in log10 scale, and the ordinate repre-
sents thepercentageof remainingcathepsinLactivity in thepresenceofsialosta-
tin L. C, relationship of the apparent dissociation constant Ki* to substrate con-
centration when reactions were initiated by the addition of cathepsin L. Values
forKi*werecalculatedasdescribedunder“Results” (cathepsinL,50pM;sialostatin
L, 0–800 pM; fluorogenic substrate, 2.5–25 M). Linear regression of the data
yields a Ki of 95.26 7.26 pM (r 0.9930). Each point in the graph is the mean
Ki* S.E. of four independent experiments.
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family C14) or cathepsins that belong to the aspartic protease
clan AA and the serine protease clan SA (cathepsins D, E, and
G). Table 1 presents the complete repertoire of enzymes tested
against tick cystatin and their class. For those inhibited by sia-
lostatin L, we further provide the inhibitor concentration nec-
essary to reduce their ezymatic activity by half (IC50) as well as
the enzyme concentration used in the assays.
All cystatins studied to date form tight equimolar complexes
with their preferred targets. A main characteristic of such
tightly binding inhibitors is that the IC50 is dependent on the
concentration of the enzyme, since the commonly used pseu-
do-first-order kinetics do not hold under those conditions. This
is also true for the inhibition of cathepsin L by sialostatin L.
When the concentration of the enzyme used in the reaction
reaches picomolar levels, an IC50 of subnanomolar range can be
achieved. Fig. 2B shows that as the concentration of the enzyme
used in the assay decreases, lower inhibitor concentration is
necessary for the same percentage of cathepsin L inhibition to
be achieved. A concomitant 2-fold reduction in the calculated
IC50 from 231 12.29 pM to 122.67 7.77 and 59.53 3.37
pM is observed, proving that sialostatin L is a tight binding
inhibitor that additionally binds stoichiometrically to
cathepsin L.We further determined that sialostatin L is a fast
binding inhibitor, since the initial velocity of the enzymatic
reaction is equally reduced, either when cathepsin L is added
to a preincubatedmix of inhibitor with substrate or when the
substrate is added to a preincubated mix of inhibitor with
enzyme (data not shown).
Since conventional Michaelis-Menten kinetics do not apply
to the study of tight binding inhibitors, because it assumes that
the free inhibitor concentration is equal to the total inhibitor
concentration, we applied Morrison’s equation for tight bind-
ing inhibition (36) to obtain apparent dissociation constants for
sialostatin L (Ki*). 50 pM of cathepsin L was allowed to interact
with increasing sialostatin L concentrations (0–800 pM) in
the presence of varying concentrations of substrate (2.5–25
M). When the Ki* for several substrate concentrations was
plotted against the substrate concentration, a linear regres-
sion line (r2  0.9930) indicated a y intercept of 95.264 
7.262 pM, which is the Ki value for the binding of sialostatin
L to cathepsin L (Fig. 2C).
Although it possesses a clear signal for secretion, the pres-
ence of sialostatin L in tick saliva was additionally verified by
Western blot. The protein content of 10 l of two different
saliva preparations was separated by electrophoresis in precast
NuPAGE 4–12% bis-Tris gradient gels (Invitrogen) and trans-
ferred to a nitrocellulose membrane (Invitrogen).Western blot
followed, using mouse anti-sialostatin L polyclonal antibodies.
A single band in the expected molecular weight was obtained
for both preparations (although fainter for the second prepara-
tion) (Fig. 3A). Next, we investigated whether the same saliva
preparations bear inhibitory activity against cathepsin L. Fig. 3B
presents the effect of tick saliva on cathepsin L activity. A final
saliva concentration, ranging from 0.2 to 0.9% (v/v) is sufficient
to cause enzymatic activity to drop in half in vitro. To clarify
whether the anti-cathepsin L activity detected in saliva corre-
sponds partially or fully to the presence of sialostatin L in it,
saliva was fractionated by chromatographic means. Fraction-
ation of the same saliva preparation was performed two times.
In the first fractionation assay, each saliva fraction was recov-
ered in 96-well plates containing assay buffer to prevent bind-
ing of the proteins to the plastic and checked for inhibition of
cathepsin L; in the second, each saliva fractionwas recovered in
96-well plates containing coating buffer to allow plastic adsorp-
tion of the proteins and subsequent sialostatin L detection
usingmouse anti-sialostatin Lpolyclonal antibodies in enzyme-
linked immunosorbent assays. The polyclonal sera used were
verified as non-cross-reactive with the second cystatin found in
FIGURE 3. Sialostatin L and cathepsin L inhibitory activity is found in two
different I. scapularis saliva preparations. A, Western blot using anti-sia-
lostatin L mouse polyclonal antibodies against the two saliva preparations.
SeeBlue prestained standard (Invitrogen) was used as a molecular weight
marker. B, both saliva preparations show anti-cathepsin L activity. The con-
centration (v/v) of saliva used in the assays is shown in the abscissa, whereas
the ordinate shows the percentage of remaining cathepsin L enzymatic activ-
ity in the presence of saliva.
TABLE 1
Effect of sialostatin L in the activity of various proteolytic enzymes
The enzymatic repertoire tested for inhibition by sialostatin L and the concentration of sialostatin L at which 50% inhibition of the activity of the targeted proteolytic
enzymes is achieved (IC50) S.E. are presented. The enzyme concentration used in the assays is also given for all the targets of sialostatin L. NI, no inhibition (e.g. inhibition
of the enzyme was not observed in the presence of 10 M sialostatin L). In the case of cathepsin B, 30% inhibition was detected at the above mentioned concentration of
inhibitor.
Enzyme Class IC50 S.E. Enzyme concentration Enzyme Class IC50
nM
Papain Cysteine protease 25.4 0.51 nM 1.5 Cathepsin D Aspartic protease NI
Cathepsin L Cysteine protease 4.68 0.08 nM 0.7 Cathepsin E Aspartic protease NI
Cathepsin V Cysteine protease 57 2.39 nM 0.9 Cathepsin G Serine protease NI
Cathepsin C Cysteine protease 112 3.58 nM 25 Legumain Cysteine protease NI
Cathepsin X Cysteine protease 937 14.06 nM 16 Calpain Cysteine protease NI
Cathepsin B Cysteine protease 10 M 0.8 Caspase 3 Cysteine protease NI
Cathepsin H Cysteine protease NI Trypsin Serine protease NI
Cathepsin S Cysteine protease NIa Elastase Serine protease NI
a See “Note Added in Proof.”
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the saliva (data not shown). The results are shown in Fig. 4, A
and B, respectively. Both the anti-sialostatin L immune reactiv-
ity and the inhibitory activity against cathepsin L describe the
same region in the chromatogram, suggesting that sialostatin L
contributes to the abovementioned inhibition of cathepsin L by
tick saliva.
Given the role of papain-like proteases in the function of the
immune system (8, 9, 37), we next investigated whether the
inhibitory action of sialostatin L can affect the proliferation of
CTL. CTLL-2 cells were cultured in the presence of 1, 3, and 10
M concentrations of the inhibitor, and cell proliferation was
monitored either by a chromogenic assay or by counting the
population of the cells under the microscope. As a negative
control, cells were cultured in the presence of recombinant
mosquito annexin ANXB9 (32, 33). All cultures were per-
formed in the presence of polymyxin B to eliminate any
potential lipopolysaccharide interference in the final results
presented in Fig. 5. A statistically significant (p  0.001)
reduction in the proliferation of cells could be detected for
all inhibitor concentrations tested, reaching up to 36% in the
presence of 3 M sialostatin L in the culture. No effect in cell
proliferation could be detected in the presence of recombinant
ANXB9.
Finally, the role of sialostatin L in acute inflammation was
evaluated in a model commonly used to test the antiinflamma-
tory potential of candidate molecules: carrageenan-induced
paw edema. As classically described (38), carrageenan induced
an edema formation that peaked at 4 h postinjection and slowly
decreased but remained significant until 24 h after injection
(the end point of the assay). When carrageenan was injected in
the presence of sialostatin L, a concentration-dependent inhi-
bitionwas observed (Fig. 6A). In the presence of a 3M concen-
tration of the inhibitor (final concentration in a total volume of
50l of injection), the decrease in the edema formation reached
30 and 22% at 1 and 4 h postinjection, respectively, but the
above mentioned differences were not statistically significant;
however, at 24 h postinjection, carrageenan-induced edema
formation was inhibited by 46% (p  0.05). Moreover, in the
presence of 10M sialostatin L, edema formation was inhibited
by 65% at 1 h (p 0.001), 54% at 4 h (p 0.001), and 75% at 24 h
postinjection (p 0.05). In a further set of experiments, carra-
geenan-induced recruitment of neutrophils in the footpads was
assessed by measuring tissue myeloperoxidase activity (34).
Mice received carrageenan injections in the absence or pres-
ence of sialostatin L. Myeloperoxidase activity in the tissue
was evaluated at 4 h postinjection, the time point at which
edema peaks (see above). A statistically significant inhibition
(p  0.001) of neutrophil recruitment was observed in the
presence of 3 and 10 M sialostatin L (Fig. 6B) that reached
51 and 60.6%, respectively. No differences in edema forma-
tion or myeloperoxidase activity could be detected when
FIGURE 4. Fractionation of saliva by chromatography shows that the
sourceof anti-cathepsin L activity andanti-sialostatin L immune reactiv-
ity coincide. A, tick saliva (10 l) was fractionated by reverse-phase high
pressure liquid chromatography into 1-min fractions collected on 96-well
plates containing Triton X-100 to prevent binding of low protein amounts to
the plastic, and these fractions were tested for cathepsin L inhibition (per-
centage of inhibition is shown in the fractionation chromatogram as a thick
black line). B, an additional 10 l of tick saliva was fractionated as above, and
each1-min fractionwas collectedon96-well plates containingcoatingbuffer,
followed by an enzyme-linked immunosorbent assay using anti-sialostatin L
polyclonal antibodies as primary antibodies. The maximum signal detected
was considered as 100% reactivity. The percentage of reactivity detected for
each saliva fraction is shown in the fractionation chromatogram as a thick
black line.
FIGURE 5. Sialostatin L inhibits the proliferation of a CTL-like cell line.
Cells were cultured in the absence (bar 1, numbering left to right) or in the
presence of 1M (bar 2), 3M (bar 3), or 10M (bar 4) sialostatin L or of 10M
mosquito annexin B9 (negative control, bar 5). Cell proliferation in the
absence of sialostatin L was considered as 100%; asterisks denote a statisti-
cally significant decrease in cell proliferation between the cells grown in the
presence of sialostatin L (p 0.001) compared with the control (cell prolifer-
ation in the absence of sialostatin L). The increase in proliferation between
cells grown in the presence of 10 M sialostatin L and those grown in the
presence of 3 M sialostatin L is not statistically significant. ctrl, control; SL,
sialostatin L.
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bovine serum albumin was co-injected with carrageenan
(negative control).
DISCUSSION
Having in hand the set of mRNA and proteins expressed in
the salivary glands of the tick I. scapularis (6), we focused on a
secreted cystatin-like molecule with a potential function in dis-
rupting tick feeding (20). The recombinant protein inhibited
papain-like proteases, targetingmainly cathepsin L and cathep-
sinC. Sialostatin L also inhibits human cathepsinV (also known
as cathepsin L2), but this protein seems to be the more closely
related homolog of mouse cathepsin L, shows high similarity
with human cathepsin L, and is probably a product of a recent
gene duplication of a cathepsin L-like gene in the human
genome (39). Finally, the high concentration of inhibitor nec-
essary to inhibit cathepsin X makes it doubtful whether this
inhibition takes place in vivo.
Certain aa substitutions in sialostatin L could contribute to
its unique specificity when compared with other cystatins. It is
almost 20 years after the first publication of an attempt to asso-
ciate certain cystatin residueswith the target specificity of those
proteins (40), and since then, a series of elegant studies (41, 42)
has shown that at least three highly conserved domainsmediate
inhibition of papain-like proteases: the N-terminal domain
located around a conserved Gly (residue 12 in the alignment of
Fig. 1B), a first hairpin loop located around the conserved
sequenceQVVAG (residues 59–63 in the alignment of Fig. 1B),
and a second hairpin loop located around two conserved PW
residues (residues 114–115 in the alignment of Fig. 1B). The
mechanism of cathepsin B inhibition by cystatin C has also
received extensive attention,mainly because cathepsin B differs
from the other family members in the vicinity of the active site
due to the presence of the so-called occluding loop (43). It has
been proposed (44) that the flexible N-terminal region of cys-
tatin C binds like an anchor to the proteinase, thus providing
the correct orientation of the inhibitor with respect to the
enzyme for displacement of the occluding loop and the subse-
quent inhibitor binding to occur. On the other hand, a substi-
tution of the Trp residue by Pro or Gly in the second hairpin
loop PW dipeptide of cystatin C reduced the affinity of the
inhibitor not only for cathepsin B but also for cathepsin H (44),
suggesting a universal role of this domain for the inhibition of
all papain-like proteases: to keep the inhibitor bound to the
enzyme once their complex has been formed. Taking into
account all of the above information, we can speculate about
the possibility that the short N terminus of sialostatin L and the
substitution of the PWmotif could potentially contribute to its
unique specificity, whereas an additional role can be attributed
to tick-specific aa substitutions found throughout the protein.
Finally, the absence of the SNDmotif (35) from the sialostatin L
sequence appears to be detrimental for its inhibitory activity
against legumain.
Cathepsin L is unique among cathepsins by having an impor-
tant extracellular function. Up to 40% of the cathepsin L proen-
zyme from fibroblasts is secreted (45) and shows catalytic activ-
ity even in the absence of further maturation processing (46).
Cathepsin L is more efficient in the degradation of protein sub-
strates than other members of the same family (47) and is more
effective in the hydrolysis of extracellular matrix proteins, such
as collagen and elastin, even when compared with collagenase
and neutrophilic elastase, which are better known for their
activity on these substrates (48, 49).
On the other hand, secreted cystatins seem to have access to
intracellular compartments (50). As a result, sialostatin L,
besides its stringent specificity, could affect the activity of addi-
tional enzymes by blocking proteolytic cascades that take place
during the maturation of their proenzymes. More specifically,
cathepsin L and S are responsible for the removal of the inhib-
itory pro-region of procathepsin C (51). In the presence of sia-
lostatin L, cathepsin L activity is inhibited, but it is still possible
that the noninhibited cathepsin S can partially (or fully) process
procathepsin C (see “Note Added in Proof”). Even if this is the
FIGURE 6. The antiinflammatory action of sialostatin L.Mice received car-
rageenan injections in their footpads either in the absence or in the presence
of 3 or 10 M sialostatin L. A, edema formation was evaluated at various time
points post-injection (abscissa) as the increase of paw thickness (in mm). B,
neutrophil recruitment in the inflamed footpadswas evaluatedbymeasuring
tissue myeloperoxidase activity, expressed as units of activity/g of tissue
(ordinate). Bar 1 (numbering left to right) represents activity detected when
carrageenan was administered to the mice, whereas bars 2 and 3 show the
effect of co-administration of 3 and 10 M sialostatin L with carrageenan,
respectively. The asterisks denote a statistically significant (p 0.001) differ-
ence in detected enzymatic activity in the footpads of mice co-injected with
carrageenan and sialostatin L compared with the control (mice that received
carrageenan injections in the absence of sialostatin L).
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case, themature cathepsinC that is producedwill be blocked by
the inhibitor. Sialostatin L inhibition of cathepsin C should also
prevent the activation of granule serine proteases in CTL and
natural killer cells (granzymes A and B), mast cells (tryptase,
proteinase 3, and chymase), and neutrophils (cathepsin G and
elastase), because the N-terminal dipeptides of their proen-
zymes would not be removed (52–54). Indeed, it could result in
prevention of cathepsin B maturation, since the trimming of
the N-terminal extensions of cathepsin B propeptide is no lon-
ger possible (55). Additionally, cathepsin L inhibition could
affect cathepsin D processing (14). From all of the above, it is
feasible that sialostatin L targets two fundamental enzymes
controlling the activation of proteolytic cascades in both the
extracellular and intracellular compartments. It seems that the
tick employs a strategy to inhibit a few (but crucial) proteases
with its saliva rather than secreting a repertoire of inhibitors
with broad target specificity.
Given the implication of the sialostatin L target enzymes in
the function of CTL (see above), we next tested whether the
presence of sialostatin L affects their proliferation. A statisti-
cally significant reduction in proliferation was detected, in
agreement with the results of Thiele et al. (56), who similarly
showed a reduction in cell proliferation when a selective chem-
ical inhibitor for cathepsin C (Gly-Phe-CHN2) was adminis-
tered in cultures of the same cell line we used, further enhanc-
ing the idea of a blockade of cathepsinC activity by sialostatin L.
Furthermore, the antiinflammatory action of sialostatin L is not
surprising, since it is known that upon onset of inflammation,
the balance between cystatins and cysteine proteases changes in
favor of proteolysis, mediating extracellular matrix remodeling
and neutrophil chemotaxis (12, 13, 57–59). Additionally, cathep-
sin L, one of the target enzymes, is implicated in kinin generation
in vivo (60). Administration of sialostatin L in the sites of inflam-
mation changed this equilibrium in favor of antiprotease activity
and reduced both edema formation and granulocyte recruitment,
as shown by the results of the myeloperoxidase assay.
Cysteine proteases have been associated with a number of
pathologic events such as cancer, rheumatoid arthritis, osteo-
arthritis, Alzheimer disease, multiple sclerosis, and muscular
dystrophy (29, 61). Our present work, in addition to revealing a
saliva constituent that contributes to its known antiinflamma-
tory and immunosuppressive properties (62, 63), describes a
novel inhibitor with a very stringent and unique specificity that
can shed more light on the role of cysteine proteases in several
biologic phenomena, including, among others, immunity and
inflammation, and may be the basis for many applications of
medical importance.
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